Cannabinoids Explained: THC, CBD, and Everything in Between
Most people know THC gets you high and CBD doesn't. But cannabis produces over 100 different cannabinoids, and the gap between what most consumers know and what's actually happening in their bodies is significant. Here's a proper breakdown.
What are cannabinoids?
Cannabinoids are chemical compounds produced by the cannabis plant that interact with your body's endocannabinoid system — a biological network of receptors found throughout your brain, nervous system, immune system, and organs. Your body actually produces its own cannabinoids naturally, called endocannabinoids. The ones from cannabis are called phytocannabinoids.
The endocannabinoid system plays a role in regulating mood, sleep, appetite, pain response, inflammation, and memory. When you consume cannabis, the phytocannabinoids interact with this system — primarily through two types of receptors called CB1 and CB2.
CB1 receptors are concentrated in the brain and central nervous system. CB2 receptors are found mostly in the immune system and peripheral tissues. Different cannabinoids bind to these receptors differently, which is why different compounds produce different effects.
THC — Tetrahydrocannabinol
THC is the primary psychoactive compound in cannabis. It binds strongly to CB1 receptors in the brain, producing the euphoric, intoxicating effect most people associate with getting high. Beyond the high, THC has well-documented effects on pain perception, nausea, appetite stimulation, and sleep. Dose matters enormously — low doses tend to produce relaxation and mild euphoria while higher doses can produce anxiety and paranoia in sensitive individuals. Start low and go slow.
THCA — Tetrahydrocannabinolic Acid
THCA is the raw, non-psychoactive form of THC found in fresh and live cannabis. The plant doesn't actually produce THC directly — it produces THCA, which converts to THC through a process called decarboxylation when exposed to heat. This is why raw cannabis doesn't get you high but smoking or vaporizing it does. THCA has shown anti-inflammatory and neuroprotective properties in early research. It's increasingly available as a concentrate or tincture for consumers who want the potential therapeutic benefits without intoxication.
THCV — Tetrahydrocannabivarin
A structural variant of THC that behaves quite differently. At low doses it appears to block CB1 receptors — potentially reducing THC intensity and suppressing appetite, the opposite of the typical cannabis munchies. At higher doses it may activate CB1 receptors and produce effects more similar to THC. Associated with energizing, clear-headed effects. Common in African sativa landrace strains and increasingly available as the market matures.
CBD — Cannabidiol
The second most abundant cannabinoid in most cannabis strains and the dominant cannabinoid in hemp. Non-intoxicating — it doesn't bind strongly to CB1 receptors. Instead it appears to modulate how other cannabinoids interact with receptors. Well-documented anti-seizure properties led to the first FDA-approved cannabis-derived medication, Epidiolex. Research also suggests anti-inflammatory and anxiolytic properties. Many consumers report CBD reduces anxiety and paranoia when combined with THC, and there's some research supporting that mechanism — though results in human trials have been mixed and it's not settled science.
CBDA — Cannabidiolic Acid
The raw acidic precursor to CBD, found in live and freshly harvested cannabis before decarboxylation. Like THCA, CBDA converts to CBD when heated. Early research suggests CBDA may have anti-nausea and anti-inflammatory properties, potentially more potent than CBD in some applications. It's more bioavailable than CBD in some delivery methods, meaning your body may absorb it more efficiently. Available in raw juices, tinctures, and some capsules.
CBG — Cannabigerol
Often called the mother of all cannabinoids because it's the precursor compound from which THC, CBD, and CBC are all synthesized as the plant matures. By harvest most of the CBG has already converted, so it's typically found in low concentrations in finished flower. Early research suggests antibacterial, anti-inflammatory, and neuroprotective properties. Consumers report a clear-headed, focused effect without intoxication. Non-psychoactive.
Two areas of particular interest: CBG has shown promise in reducing intraocular pressure in early animal studies, which has drawn attention from researchers studying glaucoma. Research from 1990 by pharmacologist Brenda Colasanti found that both THC and CBG reduced intraocular pressure when applied to cats' eyes, with CBG producing this effect without the psychoactive impact seen with THC — though human clinical trials are still limited. Many consumers also report CBG helps with headaches and migraines, which aligns with its anti-inflammatory profile and potential effects on pain signaling pathways. The research here is still catching up to the anecdotal evidence, but it's one of the more credible consumer reports in the cannabinoid space.
Interest and availability have both grown significantly in recent years.
CBGA — Cannabigerolic Acid
The acidic precursor to CBG and the foundational cannabinoid from which most other cannabinoids originate. CBGA is the starting point — enzymes in the plant convert it into THCA, CBDA, and CBCA depending on the strain's genetics. Like other acidic cannabinoids, it converts to CBG through decarboxylation. Research into CBGA's independent properties is still early but it has shown antioxidant and anti-inflammatory activity.
CBN — Cannabinol
CBN forms as THC oxidizes and degrades over time when exposed to air, heat, and light. It's why older cannabis tends to feel more sedating. CBN binds to CB1 receptors with much lower affinity than THC, producing mild sedation rather than full intoxication. Has a strong reputation as a sleep aid — while clinical research is limited, the anecdotal evidence is significant enough that many consumers specifically seek out CBN products for sleep. Also shows antibacterial properties in preliminary research.
CBC — Cannabichromene
One of the more abundant cannabinoids in the plant but far less studied than THC or CBD. Non-intoxicating — doesn't bind well to CB1 receptors. Research suggests anti-inflammatory and antidepressant properties. Appears to interact synergistically with other cannabinoids, adding another layer to the entourage effect. Also shows potential for neurogenesis — the growth of new brain cells — in early animal studies.
CBDV — Cannabidivarin
A structural analog of CBD with a similar non-intoxicating profile. Early research has focused primarily on neurological applications — it has shown promise in reducing seizure frequency and is being studied for autism spectrum disorder. Like CBD it appears to modulate rather than directly bind to cannabinoid receptors. Not widely available yet but increasingly present in research-focused products.
Bringing it all together
Most cannabinoids fall into pairs — an acidic precursor form found in the raw plant, and the active form that emerges through decarboxylation when heat is applied. THCA becomes THC. CBDA becomes CBD. CBGA becomes CBG. This is why raw cannabis doesn't get you high, and it's part of why some products are formulated specifically around the acidic, non-intoxicating forms for people who want potential therapeutic benefits without the euphoria.
The research picture varies a lot by compound. THC and CBD have decades of study behind them, including FDA-approved medications. Minor cannabinoids like CBG, CBC, CBN, and CBDV have real early research and, in some cases, genuinely compelling consumer reports — but the clinical evidence hasn't caught up yet. That gap doesn't mean the anecdotal reports are wrong. It means the science is still being built, and it's worth being honest about that difference rather than treating early findings as settled fact.
In plain terms: Cannabis isn't just THC and CBD. It's a whole family of related compounds, most of which start as an acidic form in the plant and convert into their active version with heat. Some have strong research behind them, some just have strong word of mouth, and it's worth knowing which is which before you decide what you're actually looking for.
TL;DR: THC gets you high, THCA doesn't until it's heated. CBD doesn't get you high and may help balance THC's more intense effects. THCV can suppress appetite instead of triggering munchies. CBG and CBC are non-intoxicating with early promising research on inflammation and pain. CBN is what forms as THC ages, and it's become the go-to for sleep. CBDA and CBDV are less common but showing up more as research expands. Most of these compounds have real potential — the science on the minor ones just hasn't fully caught up to what consumers are already reporting.
If you're not sure which cannabinoid profile fits what you're looking for, ask us. We can walk you through what's actually in a product beyond just the THC percentage on the label.
Sources
Gaoni Y, Mechoulam R (1964) — Isolation, structure and partial synthesis of an active constituent of hashish — Journal of the American Chemical Society
Colasanti BK (1990) — Ocular hypotensive effect of cannabinoids in cats — cited in later reviews of cannabinoid ocular pharmacology
Devinsky O et al. (2017) — Trial of Cannabidiol for Drop-Resistant Seizures in the Dravet Syndrome — New England Journal of Medicine (Epidiolex approval research)
McPartland JM, Russo EB (2001) — Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? — Journal of Cannabis Therapeutics
Russo EB (2011) — Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects — British Journal of Pharmacology
